Assessment of whole-blood bactericidal activity in the evaluation of new antituberculosis drugs

Antituberculosis Chemotherapy

Volumn 10, Issue , 2011, Pages 220-226

  Wallis, Robert S ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84871252622     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000324636     Document Type: Chapter

References (29)

1. Mitchison DA: The action of antituberculosis drugs in short-course chemotherapy. Tubercle 1985;66:219-225.
2. Zhang Y, Mitchison D: The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003;7:6-21.
3. Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A: Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 2010;10:68-69.
4. Jindani A, Dore CJ, Mitchison DA: Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003;167:1348-1354.
5. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, Coleman DJ, Fourie B, Mitchison DA:A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-138.
6. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, Vernon A, Chaisson RE:Moxifloxacin versus ethambutol in the first two months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338.
7. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE: Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183-1189.
8. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, Guy E, Guyadeen P, Leus MC, Maltas G, Menzies D, Nuermberger EL, Villarino M, Vernon A, Chaisson RE: Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280.
9. Janulionis E, Sofer C, Schwander S, Simmons D, Kreiswirth B, Shashkina E, Wallis RS: Survival and replication of clinical Mycobacterium tuberculosis isolates in the context of human innate immunity. Infect Immun 2005;73:2595-2601.
10. Wallis RS, Palaci M, Vinhas S, Hise AG, Ribeiro FC, Landen K, Cheon SH, Song HY, Phillips M, Dietze R, Ellner JJ: A whole blood bactericidal assay for tuberculosis. J Infect Dis 2001;183:1300-1303.
11. Cheon SH, Kampmann B, Hise AG, Phillips M, Song HY, Landen K, Li Q, Larkin R, Ellner JJ, Silver RF, Hoft DF, Wallis RS: Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol 2002;9:901-907.
12. Saliu O, Sofer C, Stein DS, Schwander SK, Wallis RS: Tumor necrosis factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006;194:486-492.
13. Hoft DF, Worku S, Kampmann B, Whalen CC, Ellner JJ, Hirsch CS, Brown RB, Larkin R, Li Q, Yun H, Silver RF: Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis 2002;186:1448-1457.
14. Kampmann B, Tena-Coki GN, Nicol M, Levin M, Eley B: Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART. AIDS 2006;20:1011-1018.
15. Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, Packe GE, Davidson RN, Eldridge SM, Maunsell ZJ, Rainbow SJ, Berry JL, Griffiths CJ: A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007;176:208-213.
16. Wallis RS, Vinhas SA, Johnson JL, Ribeiro FC, Palaci M, Peres RL, Sa RT, Dietze R, Chiunda A, Eisenach K, Ellner JJ: Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis 2003;187:270-278.
17. Wallis RS, Vinhas S, Janulionis E: Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. Tuberculosis (Edinb) 2009;89:221-224.
18. Wallis RS, Weyer K, Fourie PB: Acquired rifamycin resistance: pharmacology and biology. Expert Rev Anti Infect Ther 2008;6:223-230.
19. Hui M, Au-Yeang C, Wong KT, Chan CY, Yew WW, Leung CC: Post-antibiotic effects of linezolid and other agents against Mycobacterium tuberculosis. Int J Antimicrob Agents 2008;31:395-396.
20. Wallis RS, Patil S, Cheon SH, Edmonds K, Phillips M, Perkins MD, Joloba M, Namale A, Johnson JL, Teixeira L, Dietze R, Siddiqi S, Mugerwa RD, Eisenach K, Ellner JJ: Drug tolerance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1999;43:2600-2606.
21. Wallis RS, Song HY, Whalen C, Okwera A: TB chemotherapy: antagonism between immunity and sterilization. Am J Respir Crit Care Med 2004;169:771-772.
22. Sala C, Dhar N, Hartkoorn RC, Zhang M, Ha YH, Schneider P, Cole ST: A simple model for testing drugs against non-replicating Mycobacterium tuberculosis. Antimicrob Agents Chemother 2010;54:4150-4158.
23. Wallis RS, Kumar V, Jakubiec W, Silvia AM, Paige D, Bedarida G, Mitton-Fry M, Miller PF:Safety, tolerability, PK, and WBA of multiple ascending doses of PNU-100480 (abstract A1-030a). ICAAC, Boston, September 2010.
24. Wallis RS, Jakubiec W, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF: Pharmacokinetics and whole blood bactericidal activity against Mycobacterium tuberculosis of single ascending doses of PNU-100480 in healthy volunteers. J Infect Dis 2010;202:745-751.
25. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E: Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model. Antimicrob Agents Chemother 2008;53:1314-1319.
26. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL: Addition of PNU-100480 to firstline drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009;180:371-376.
27. Koh WJ, Kwon OJ, Gwak H, Chung JW, Cho SN, Kim WS, Shim TS: Daily 300 mg dose of linezolid for the treatment of intractable multidrugresistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009;64:388-391.
28. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL:Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med 2008;178:1180-1185.
29. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TC, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF: Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:2831-2835.